IBS Subgroups For Lotronex Need Better Definition, Advisory Cmte. Says
Executive Summary
The subgroup of irritable bowel syndrome patients for whom GlaxoSmithKline's Lotronex is most effective needs better definition, members of a joint FDA advisory committee meeting suggested